Financial Performance - The company's operating revenue for the first half of 2024 reached ¥759,894,679.84, representing a 17.09% increase compared to the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥11,877,328.48, a significant recovery from a loss of ¥47,561,505.48 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥21,530,307.28, compared to a loss of ¥71,740,894.74 in the same period last year[12]. - The net cash flow from operating activities was -¥34,029,158.20, an improvement from -¥87,139,193.83 in the previous year[12]. - The total assets at the end of the reporting period were ¥3,098,824,269.38, reflecting a 2.23% increase from the previous year[12]. - The net assets attributable to shareholders of the listed company decreased by 1.22% to ¥1,606,230,170.26 compared to the end of the previous year[12]. - The company achieved a net profit attributable to shareholders, marking a significant increase compared to the same period last year, primarily due to a 17.09% increase in revenue from core products including Yipuding, Sairuojin, and Baitexi[13]. - The basic earnings per share for the reporting period was not applicable, with diluted earnings per share also not applicable, reflecting a shift from a loss of 0.24 yuan per share in the previous year[13]. - The weighted average return on equity after deducting non-recurring gains and losses was 1.33%, a recovery from -4.01% in the same period last year[13]. - The company reported a revenue of 12,352.7 billion RMB in the first half of 2024, a year-on-year decline of 0.9%[22]. Research and Development - Research and development expenses accounted for 11.52% of operating income, a decrease of 18.49 percentage points compared to the previous year[13]. - The company has established a comprehensive R&D system with capabilities spanning drug discovery to industrialization, focusing on recombinant protein drugs and antibody drugs[21]. - The company has 12 innovative drug projects in focus, with multiple projects entering the process development stage[29]. - The company has achieved significant milestones in R&D, including breakthroughs in high-concentration formulations and eukaryotic expression systems[23]. - The company’s antibody drug development platform has successfully supported the development of multiple projects, including GB10 and GB18, with promising lead compounds[23]. - The company has invested CNY 87.54 million in R&D during the reporting period, focusing on antiviral, oncology, immune, and degenerative diseases[41]. - The first self-developed Class 1 innovative drug, Fc fusion protein-long-acting growth hormone, has entered Phase I clinical trials, and the inhalation solution of human interferon α1b is in Phase III trials[39]. - The company is focusing on the development of new therapies for chronic diseases, including multiple myeloma and breast cancer, to enhance its product portfolio[20]. Market Position and Product Development - The company has established strategic partnerships with several pharmaceutical companies to commercialize key drugs, enhancing its market presence in over 70 countries[17]. - The market share of Sairuojin® in the domestic short-acting interferon market remains the highest, while Yipuding ranks second in the domestic erythropoietin market[17]. - The company is actively expanding its oncology product line, including the introduction of Paclitaxel for various cancer treatments, indicating a focus on growth in the oncology sector[20]. - The company has submitted a listing application for its Palbociclib capsules in the U.S., reflecting its international market ambitions[20]. - The company’s biosimilar Infliximab has been recognized for its efficacy and safety, being the first of its kind launched in China, which strengthens its competitive edge[20]. - The company has developed a patented formulation of Erythropoietin that reduces blood-borne contamination and allergic reactions, making it one of only two manufacturers in China for a specific indication[18]. - The company has obtained registration for its traditional Chinese medicine product in Hong Kong, indicating its market expansion efforts[20]. - The company introduced 13 new products, focusing on oncology, autoimmune diseases, and metabolic diseases, to support its overseas commercialization strategy[35]. Financial Management and Investments - The company has established a marketing distribution network covering nearly 22,700 terminals in the domestic market[21]. - The company has established a marketing network covering approximately 7,000 hospitals in China, enhancing its market position and brand advantage[32]. - The company has invested a total of CNY 200,000,000.00 in a private equity fund aimed at expanding potential cooperation opportunities in the health industry[53]. - The company has recognized a cumulative profit impact of CNY -13,940,667.35 from its private equity investments[54]. - The total amount of raised funds is CNY 110,924.94 million, with a net amount after issuance costs of CNY 99,464.09 million[110]. - The company has utilized CNY 25,000 million of idle raised funds for cash management, with a cash management balance of CNY 7,000 million at the end of the reporting period[115]. - The company has received regulatory warnings for non-compliance in cash management of raised funds but has rectified the situation by redeeming non-principal guaranteed financial products[116]. Environmental and Social Responsibility - The company has invested 670,500 CNY in environmental protection during the reporting period[60]. - The company operates wastewater treatment facilities with a total design capacity of 1,100 m³/d, all running normally[61]. - The company has established an emergency response plan for environmental incidents, with a validity period of three years[65]. - The company has implemented an online monitoring system for wastewater and conducts regular third-party testing for emissions[66]. - The company has confirmed compliance with pollution discharge standards, with no exceedances reported[60]. - The company has received environmental impact assessment approvals for new projects, including the industrialization of polyethylene glycol-stimulated human granulocyte colony-stimulating factor injection[64]. - The company actively responds to the national "carbon neutrality" strategy by adopting low-carbon energy-saving measures and utilizing new technologies to reduce greenhouse gas emissions[70]. Corporate Governance and Compliance - The company has commitments from major shareholders and management regarding share restrictions, effective from March 31, 2020, until December 13, 2025, ensuring compliance with lock-up periods[71]. - The company has not reported any mergers or acquisitions during the reporting period[69][70][71][72]. - The company will publicly explain any failure to fulfill commitments made during the IPO and apologize to shareholders and public investors[90]. - The company will ensure that any stock incentive plans are tied to the execution of measures to compensate for diluted returns[82]. - The company has maintained a good credit status, with no significant debts that are overdue or unfulfilled[102]. - The company received administrative regulatory measures from the China Securities Regulatory Commission and the Shanghai Stock Exchange in August 2024, indicating compliance issues that require rectification[101]. Shareholder Information - The total number of ordinary shareholders as of the reporting period is 9,456[119]. - The company reported a total of 131,778,347 shares outstanding, with significant holdings from major shareholders including 1,764,125 shares held by the chairman, Deng Xueqin[120]. - Deng Xueqin increased his shareholding by 762,710 shares during the reporting period, reflecting a strong confidence in the company's future[121]. - The company granted a total of 780,000 new restricted stocks to key management personnel, indicating a commitment to incentivize and retain talent[122]. - The total number of shares held by the top ten shareholders includes a significant portion of 1,880,572 shares held by a repurchase account, representing 0.94% of the total shares[120]. Asset and Liability Management - The total liabilities as of June 30, 2024, were CNY 1,486.24 million, compared to CNY 1,400.30 million at the end of 2023, reflecting an increase of approximately 6.1%[127]. - The total assets reached CNY 3,098.82 million, up from CNY 3,031.09 million, indicating a growth of about 2.2%[127]. - The company's cash and cash equivalents decreased to CNY 439.76 million from CNY 568.80 million, a decline of approximately 22.7%[125]. - The total equity attributable to shareholders decreased to CNY 1,606.23 million from CNY 1,626.02 million, a decline of about 1.2%[127]. - The inventory level decreased to CNY 155.87 million from CNY 191.36 million, a reduction of approximately 18.5%[125].

证券代码：688136 证券简称：科兴制药 公告编号：2024-059 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 根据《中华人民共和国证券法》、中国证监会《公开发行证券的公司信息披 露内容与格式准则第 3 号——半年度报告的内容与格式》、《上海证券交易所科 创板股票上市规则》等有关规定,董事会全体成员对公司《2024 年半年度报告》 及《2024 年半年度报告摘要》进行审阅。公司 2024 年半年度报告未经会计师事 务所审计；经本次董事会审议通过后，同意对外报送公司《2024 年半年度报告》 及《2024 年半年度报告摘要》。 科兴生物制药股份有限公司 第二届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会第十七次会议 于 2024 年 8 月 19 日在深圳市南山区创益科技大厦 B 栋 19 楼会议室以现场结合 通讯的方式召开。本次会议通知于 202 ...

上 海 证 券 交 易 所 关于对科兴生物制药股份有限公司及有关责任 人予以监管警示的决定 上证科创公监函〔2024〕0036 号 当事人： 科兴生物制药股份有限公司，A 股证券简称：科兴制药，A 股证券代码：688136； 邓学勤，科兴生物制药股份有限公司时任董事长； 赵彦轻，科兴生物制药股份有限公司时任总经理； 王小琴，科兴生物制药股份有限公司时任财务总监兼董事 会秘书。 根据中国证券监督管理委员会山东监管局《关于对科兴生物 制药股份有限公司采取责令改正、出具警示函措施的决定》 （〔2024〕76 号）和《关于对邓学勤、赵彦轻、王小琴采取出具 警示函措施的决定》（〔2024〕77 号）（以下合称《行政监管措施》） 查明的事实，科兴生物制药股份有限公司（以下简称科兴制药或 公司）存在下列违规行为。 二是未保持自愿信息披露的持续性。2022 年，公司自愿披 露了人干扰素α2b 泡腾胶囊临床试验申请获得受理、收到药物 临床试验批准通知书等公告。但是，该项目于 2024 年 1 月终止， 公司未及时披露相关终止情况，仅在 2023 年年报中予以披露。 三是使用募集资金进行现金管理不规范。2023 年以来，公 司存 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-057 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司 关于注销部分募集资金专户的公告 科兴生物制药股份有限公司(以下简称"公司")近日办理完成部分募集资金 专项账户的注销手续，现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655号）同意，公司首次公开发 行人民币普通股4,967.5300万股，每股面值人民币1.00元，每股发行价为人民币 22.33元，本次发行募集资金总额为1,109,249,449.00元，扣除保荐承销等发行 费用114,608,529.84元，募集资金净额为994,640,919.16元。上述募集资金已全 部到位，经大华会计师事务所（特殊普通合伙）验资，并于2020年12月7日出具 大华验字[2020]000752号《验资报告》验证确认。 上述募集资金到账后，公司依照规定对上述募集资金进行专户存储 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-058 科兴生物制药股份有限公司 关于公司及相关人员收到中国证券监督管理委员会山东监管局 《行政监管措施决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）及相关人员于近日分别收 到中国证券监督管理委员会山东监管局（以下简称"山东监管局"）下达的《行 政监管措施决定书》（〔2024〕76号、77号），现就主要内容公告如下： 一、《行政监管措施决定书》内容 "科兴生物制药股份有限公司、邓学勤、赵彦轻、王小琴： 前期，我局对你公司开展了现场检查。经查，你公司存在以下问题: 一、2023年年度业绩预告信息披露不准确。2024年1月31日，你公司披露《2023 年年度业绩预告》，预计2023年度实现归属于母公司所有者的净利润为-11,000 万元到-8,500万元，扣除非经常性损益后的净利润为-12,000万元到-9,500万元。 2024年2月24日，你公司披露《2023年年度业绩预告更正公告》，更正后预计20 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-056 科兴生物制药股份有限公司 关于实际控制人兼董事长、董事及高级管理人员增持股份计划 实施完毕暨增持结果的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 增持计划基本情况：科兴生物制药股份有限公司（以下简称"公司"）董 事长邓学勤先生，董事、总经理赵彦轻先生，董事、董事会秘书兼财务总监王小 琴女士，董事、副总经理崔宁女士以及副总经理邵珂先生、马鸿杰女士基于对公 司未来发展前景的信心、对公司价值的认可和切实履行社会责任，计划自 2024 年 1 月 31 日起 6 个月内，通过上海证券交易所交易系统允许的方式（包括但不 限于集中竞价、连续竞价和大宗交易等）增持公司 A 股股份，合计增持金额不低 于人民币 1,300 万元且不超过人民币 2,600 万元。增持计划的具体内容详见公司 2024 年 2 月 1 日于上海证券交易所网站（www.sse.com.cn）披露的《关于实际 控制人兼董事长、董事及高级管理人员增持股份计划暨 ...

北京市嘉源律师事务所 关于科兴生物制药股份有限公司 实际控制人免于以要约方式 增持股份的专项核查意见 事务所 IIA YUAN LAW OFFICES 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 释 义 除非专项核查意见另有说明,下列词语之特定含义如下: | 科兴制药、公司 | 指 | 科兴生物制药股份有限公司,为一家依据中国法律成立并有效 存续的股份有限公司,其发行的股票依法在上海证券交易所科 | | --- | --- | --- | | | | 创板上市交易,股票代码:688136 | | 增持人 | 指 | 邓学勤先生 | | 中国证监会 | 指 | 中国证券监督管理委员会 | | 上交所 | 指 | 上海证券交易所 | | 本次增持 | 指 | 增持人于 2024年1月31日至2024年7月30日期间以自有 资金通过上交所集中竞价交易方式合计增持公司股份 762,710 | | | | 股,占公司总股本 199,198,650 股的 0.38%。 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | 《收购管理办法 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-055 科兴生物制药股份有限公司 自愿披露关于注射用紫杉醇（白蛋白结合型） 获欧盟委员会上市批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）合作伙伴浙江海昶生物医 药技术有限公司于近日收到欧盟委员会（European Commission）通知，公司引 进产品注射用紫杉醇（白蛋白结合型）（Apexelsin®，以下简称"白蛋白紫杉醇"） 获得欧盟委员会上市批准。 现将相关情况公告如下： 一、药品相关情况 二、主要产品的市场情况 注射用紫杉醇（白蛋白结合型）剂型具备临床用药优势，相对普通紫杉醇注 射液和紫杉醇脂质体，安全性和患者依从性有所提升，临床认可度较高，在肿瘤 治疗领域具有不可或缺的临床价值。 白蛋白紫杉醇是欧洲医学肿瘤学会指南中治疗乳腺癌、转移性胰腺癌和非小 细胞肺癌的推荐用药。过去五年，欧洲癌症发病率呈上升趋势，白蛋白紫杉醇销 量在欧洲市场逐步增长。 三、对公司的影响 本次白蛋白紫杉醇获得欧盟集中 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-054 科兴生物制药股份有限公司 关于开立募集资金专项账户并签订募集资金专户存储三方监管协议 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655号）同意，科兴生物制药股 份有限公司（以下简称"公司"）首次公开发行人民币普通股4,967.5300万股， 每股面值人民币1.00元，每股发行价为人民币22.33元，本次发行募集资金总额 为1,109,249,449.00元，扣除保荐承销等发行费用114,608,529.84元，募集资金 净额为994,640,919.16元。上述募集资金已全部到位，经大华会计师事务所（特 殊普通合伙）验资，并于2020年12月7日出具大华验字[2020]000752号《验资报 告》验证确认。 上述募集资金到账后，公司依照规定对上述募集资金进行专户存储管理，并 与保荐机构中信建投证券股份 ...

Summary of Conference Call Company and Industry - The document pertains to the pharmaceutical industry, specifically focusing on a company named 科兴制药 (Sinovac Biotech) [1]. Core Points and Arguments - The company has achieved extensive coverage in emerging markets [1]. - A total of 13 products have been introduced by the company [1]. - The company has launched an equity incentive plan aimed at supporting its overseas commercialization strategy [1]. Other Important Content - The call featured an online discussion with the head of investor relations, Mr. Duan, from Sinovac Biotech [1].